Nuestro colaborador global, Alianza GIST comparte el artículo "El tratamiento de pacientes con cáncer y la contención de COVID-19: experiencias de Italia "por el Dr. Giuseppe Curigliano publicado en el ASCO Daily News. Este artículo también está disponible en inglés.
In this critical time, the FDA Oncology Center of Excellence wants you to know that we are here for patients with cancer and their health care providers and we will do everything we can to help you through the coronavirus crisis.
During this webcast presentation, Dr. Michael Heinrich will discuss these two new treatment options for advanced GIST. Dr. Heinrich will explain how each of these drugs works to target mutations for which there has previously been no targeted treatment and discuss the current coronavirus outbreak.
LRG members Jennifer & Owen Moore give their perspective on participating in the Phase I BLU-285 trial at OSHU with Dr. Michael Heinrich. After three other drug treatment lines and faced with several growing tumors, the BLU-285 (avapritinib) trial was Owen’s best option.
The Life Raft Group announces Steve Pontell, Esq. as the newest addition to our Board of Directors.
Deb Melikian, patient advocate, and Dr. Jason Sicklick, GIST expert & researcher, share the story of their unique partnership which began at an LRG GIST Day of Learning in the rare partners issue of RARE Revolution Magazine.
Blueprint Medicines announced that the FDA has approved AYVAKIT™ (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.
CTOS, "The Connective Tissue Oncology Society", is an organization of medical specialists and researchers who specialize in bone and soft tissue tumors. They hold a meeting every year to discuss the latest innovations in this area. This year the meeting took place in Tokyo from November 13 until 16.
The UK National Cancer Research Institute’s (NCRI) annual conference was held on November 3rd-5th. This year the conference was held in Glasgow (Scotland).
Breaking news in Targeted Oncology online today - A New Drug Application (NDA) for Ripretinib (DCC-2618) was submitted to FDA for treatment of GIST, by Deciphera.
